FIELD: chemistry.
SUBSTANCE: pharmaceutical composition includes a compound of formula 
(I) or a pharmaceutically acceptable salt thereof, an acid additive and inert filler. As the acid additive alginic acid or silicon dioxide is used.
EFFECT: enhanced storage stability of the specified composition.
9 cl, 19 ex, 7 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION INCLUDING AMIDE DERIVATIVE, INHIBITING CANCER CELLS GROWTH, AND NON-METAL SALT LUBRICANT | 2012 |
|
RU2632099C2 |
| STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING LEVOCETIRIZINE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND MONTELUKAST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2013 |
|
RU2614382C2 |
| ENCAPSULATED DOSAGE FORM, CONTAINING MONTELUKAST AND LEVOCETIRIZINE | 2012 |
|
RU2606857C2 |
| PHARMACEUTICAL CAPSULE COMPOSITE FORMULATION CONTAINING TADALAFIL AND TAMSULOSIN | 2014 |
|
RU2672573C2 |
| PHARMACEUTICAL COMPLEX COMPOSITION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2016 |
|
RU2724338C2 |
| COMPLEX PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE, LOSARTAN AND CHLORTHALIDONE | 2016 |
|
RU2713883C2 |
| PHARMACEUTICAL COMBINATION FORMULATION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2014 |
|
RU2660586C1 |
| PHARMACEUTICAL COMBINED COMPOSITION | 2016 |
|
RU2736942C2 |
| SOLID DISPERSION WITH IMPROVED SOLUBILITY COMPRISING TETRAZOLE DERIVATIVE AS AN ACTIVE INGREDIENT | 2013 |
|
RU2662819C2 |
| SOLID PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPINE AND LOSARTAN | 2015 |
|
RU2698703C2 |
